Latest Immunotherapy News
- BSO Conductor Has Kidney Removed 23 Jul 2008 11:50 GMT
... and chemotherapy is reserved for advanced cases. Further surgery, treatment with targeted therapies or immunotherapy could be considered in cases of cancers that recur after initial surgery, the American Cancer ...
- Growth On James Levine's Kidney Found To Be Malignant 23 Jul 2008 10:32 GMT
... that has not expanded beyond the organ. Additional surgery, treatment with targeted therapies or immunotherapy could be taken into account in cases of cancers that reappear after initial surgery, the ...
- Conductor James Levine had bad kidney 23 Jul 2008 09:36 GMT
... and chemotherapy is reserved for advanced cases. Further surgery, treatment with targeted therapies or immunotherapy could be considered in cases of cancers that recur after initial surgery, the American Cancer ...
- Conductor James Levine had malignant kidney growth 23 Jul 2008 03:31 GMT
... and chemotherapy is reserved for advanced cases. Further surgery, treatment with targeted therapies or immunotherapy could be considered in cases of cancers that recur after initial surgery, the American Cancer ...
- Tobacco Used To Make Cancer Vaccine 22 Jul 2008 18:33 GMT
... In an ironic twist to the relationship between tobacco and ... administer, and a viable option for idiotype-specific immune therapy in follicular lymphoma patients." The vaccine works because ...
- IRX Therapeutics Announces Results of Phase 2 Study for IRX-2 22 Jul 2008 15:30 GMT
... announced preliminary findings from its Phase 2 clinical trial of IRX-2, the Company's investigational immunotherapy for head & neck cancer. The preliminary results of the study suggest that IRX-2 is ...
- Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in the American Cancer Society's Journal Cancer 22 Jul 2008 13:17 GMT
... Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in the American Cancer Society's Journal Cancer Cell Genesys, Inc. (Nasdaq:CEGE) ...
- Vical Receives $1 Million Milestone Payment From AnGes MG for Angiogenesis Program 22 Jul 2008 11:00 GMT
... for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in ...
- Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age 22 Jul 2008 04:32 GMT
... Unable to Deliver Requested Page In order to use Medscape, your browser must be set to accept ...
- New therapy targets the body's immune response to brain protein 21 Jul 2008 19:58 GMT
... New therapy targets the body's immune response to brain protein ... and principal investigator for the clinical trial. "Immune therapy has promise for being able to modify the ...
- Immunotherapy May Boost Prostate Cancer Response to Hormone Therapy 21 Jul 2008 19:15 GMT
... Immunotherapy May Boost Prostate Cancer Response to Hormone Therapy NEW YORK JULO 21, 2008 (Reuters Health) ...
- Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID Anti-Cancer Vaccine Results 21 Jul 2008 13:52 GMT
... Myeloma. Biovest International, Inc. (OTCBB:BVTI) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, ...
- Provectus Pharmaceuticals Adds M.D. Anderson as First U.S. Center to Phase 2 Clinical Trial Of PV-10 21 Jul 2008 13:52 GMT
... M. D. Anderson for cancer care in the form of surgery, chemotherapy, radiation therapy, immunotherapy, or combinations of these and other treatments. This multidisciplinary approach to treating cancer was pioneered ...
- Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID(R) Anti-Cancer Vaccine Results 21 Jul 2008 12:30 GMT
... Leukemia and Multiple Myeloma. ) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, ...
- Exelixis Initiates Phase 3 Trial of XL184 in Medullary Thyroid Cancer 21 Jul 2008 10:30 GMT
... including tyrosine kinase inhibitors with anti-RET activity (e.g., vandetanib, sorafenib, or motesanib), chemotherapeutic agents, immunotherapy, radioactive iodine, and radiotherapy. Additional clinical studies with XL184 are ongoing to complement the pivotal ...
- Introgen To Present ADVEXIN Phase 3 Study Results At American Association For Cancer Research's Cancer Clinical Trials 21 Jul 2008 09:34 GMT
... therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using ...
- American Society For Microbiology Honors Rosenberg, Baselsk, De Lorenzo And Clapham 20 Jul 2008 10:18 GMT
... of cancer. His major achievements include the development of interleukin-2 as the first effective immunotherapy for cancer, identification of more than two dozen human cancer associated antigens used in studies ...
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
|
washingtonpost.com:
cbsnews.com:
bbc.co.uk:
canada.com:
abcnews.go.com:
healthday.com:
